The AstraZeneca share price is climbing. Is growth really here again?

The AstraZeneca share price has been volatile in recent years, though we’ve seen a strong run since March. Will I buy at today’s valuation?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After Pascal Soriot took the helm during crisis time at AstraZeneca (LSE: AZN), it was always going to take a while to turn things round. Maybe about five years, I thought, back in 2012. Still, the pharmaceuticals giant recorded a hefty 2020 profit rise after several years of falls. And the AstraZeneca share price had already been gaining in anticipation of a return to long-term growth.

Since early 2019, the shares have been climbing. And over a five-year period, they’ve more than doubled in price. The last 12 months have been a bit rocky, with the company getting into troubles with the European Union over shipments of Covid-19 vaccine.

But, since early March, we’re looking at a steady rise again. A first-quarter earnings call at the end of April gave AstraZeneca shares another boost, and they’ve continued upwards since. My Motley Fool colleague Pam Narang has picked up on some of the main points of AstraZeneca’s key drug developments, so I won’t repeat them here.

But, to summarise, AstraZeneca is making impressive progress in its key lines of oncology and diabetes research. So I really don’t think we should see the AstraZeneca share price as a Covid-19 play. I do fear, however, that’s how a lot of investors see it right now.

AstraZeneca share price valuation

Will I buy? That depends on whether the company really has got its pipeline primed to produce regular successes in the coming years. And if I think we can expect a period of steady earnings growth. I can’t tell from the Q1 figures, which were skewed by the disposal of AstraZeneca’s 26.7% share of Viela Bio. That raised a profit of $776m. First-half results, due in July, will be fuller and will hopefully give me a better insight.

In the meantime, I’m thinking about the AstraZeneca share price valuation. They ended 2020 on a P/E of around 40. And this year’s share price gains push that trailing multiple as high as 47. That’s the kind of level I’d expect for a smaller growth stock, and it does seem to assume there’ll be some stellar growth from AstraZeneca in the next few years.

And AstraZeneca shares have been volatile, and do seem to be cyclical. Even with no obvious change in the company’s long-term outlook, investors can swing from not touching it with a bargepole, to pumping it up like the next great growth stock.

Waiting for steadier times

As I suggested, I really do think Covid-19 lies behind a lot of the current AstraZeneca share price bullishness. But I don’t expect it to figure greatly in the company’s long-term future. Covid has quickly become one of the world’s best-researched ailments. While the worldwide effort has been nothing short of remarkable, it does mean there’s huge competition out there for these vaccines.

Right now, I’m not going to buy. Today’s valuation, and the Covid-19 effect, make me want to wait until things are more settled. And when the dividend starts rising again, that’s when I’ll be truly convinced that sustainable earnings growth is back.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »